{"id":2622,"date":"2025-12-04T10:39:47","date_gmt":"2025-12-04T08:39:47","guid":{"rendered":"https:\/\/thesciencesupport.com\/?p=2622"},"modified":"2025-12-04T16:19:03","modified_gmt":"2025-12-04T14:19:03","slug":"the-evolution-of-nipt","status":"publish","type":"post","link":"https:\/\/thesciencesupport.com\/en\/the-evolution-of-nipt\/","title":{"rendered":"The Evolution of NIPT: How Cell-Free DNA Testing Is Elevating Prenatal Screening"},"content":{"rendered":"

Non-invasive prenatal testing (NIPT) using cell-free DNA (cfDNA) has transformed prenatal screening and care over the last decade. Nowadays, cfDNA-based NIPT has evolved into a central tool for early and accurate risk assessment of common fetal chromosomal aneuploidies, reshaping how clinicians counsel expectant parents, how laboratories deliver services, and how healthcare systems plan prenatal pathways.<\/p>\n

Below, we explain the science behind cfDNA, why NIPT offers accuracy advantages over older approaches, and how Revvity\u2019s Vanadis\u00ae NIPT system<\/strong><\/a> helps laboratories offer precise, scalable, and cost-effective screening.<\/p>\n

What is cfDNA and how does NIPT work?<\/strong><\/h3>\n

During pregnancy, short fragments of DNA circulate in the mother\u2019s blood plasma. A fraction of this cell-free DNA originates from the placenta and reflects the fetal genome. NIPT analyses these cfDNA fragments to detect over- or under-representation of whole chromosomes\u00a0(most commonly chromosomes 21, 18, and 13) and, in some workflows, selected sex-chromosome abnormalities (SCAs)<\/a><\/strong>, such as Turner (45,X) <\/a><\/strong>or Klinefelter syndrome (47,XXY<\/a>)<\/strong>.<\/p>\n

Different laboratory approaches exist to measure cfDNA (e.g., massively parallel sequencing, targeted sequencing, SNP-based methods, and non-PCR methods). Revvity\u2019s Vanadis\u00ae cfDNA platform<\/strong><\/a> uses a rolling circle replication and digital molecular counting approach that reduces complexity by avoiding PCR and sequencing while still delivering high precision and reproducibility for common trisomies.<\/p>\n

Why NIPT is more accurate than conventional screening<\/strong><\/h3>\n

Traditional first-trimester screening (NT ultrasound + serum biochemistry) provides useful risk estimates but has inherent limits in sensitivity and positive predictive value. In contrast, cfDNA-based NIPT delivers substantially higher detection rates for trisomy 21 (Down syndrome)<\/strong><\/a> \u2014 often above 99% sensitivity with very low false positive rates \u2014 and generally improved performance for trisomies 18 (Edward syndrome)<\/strong><\/a> and 13 (Patau syndrome)<\/strong><\/a> as well. Multiple meta-analyses and clinical studies have confirmed that all major NIPT methods greatly outperform standard combined screening in sensitivity and specificity for common fetal aneuploidies.<\/p>\n

Practical benefits of the increased accuracy include:<\/p>\n